IN THE CLAIMS:

Please cancel Claims 1-107 without prejudice to, or disclaimer of, the subject matter contained therein.

Please add new claims 108-150 as follows:

(New) A pharmaceutical composition comprising:

a compound having the formula

W¹—R¹—Ar²—R²—W²

or salts thereof,

wherein


each of W¹ and W² is independently CO₂R³, C(=NH)NH(OH), PO(OR³)₂ or C(=O)CF₃;

each of R¹ and R² is a bond, CH₂ or C₁-C₆ alkylene;

each of Ar¹ and Ar² is independently C₃—C₂₀ aryl/or C₁-C₂₀ heteroaryl;

L is a linker comprising from 1 to about 20 atoms; and,

R3 is hydrogen or C₁-C₆ alkyl.




110. (New) The composition of Claim 108, wherein said compound is of the formula:

$$W^1 - R^1 - Ar^1 - L - R^2 - W$$


111. (New) The composition of Claim 108, wherein said compound is of the formula:

$$W^1 \longrightarrow R^1 \longrightarrow L \longrightarrow R^2 \longrightarrow W$$

- 112. (New) The composition of Claim 108, wherein L is selected from the group consisting of C_1 - C_{20} alkoxy, C_6 - C_{20} aryland C_1 - C_6 heteroaryl.
 - 113. (New) The composition of Claim 112, wherein L is -CH₂O-.
 - 114. (New) The composition of Claim 112, wherein L is a moiety of the formula:



115. (New) The composition of Claim 112, wherein L is a moiety of the formula:



wherein each of R^4 and R^5 is independently H, C_1 - C_6 alkyl, C_8 - C_{10} aralkyl or a

protecting group.

116. (New) The composition of Claim 108, wherein the compound is of the formula:

117. (New) The composition of Claim 108, wherein the compound is of the formula:

$$H_2O_3P$$
 PO_3H_2


119. (New) The composition of Claim 108, wherein the compound is of the formula:

120. (New) The composition of Claim 108, wherein the compound is of the formula:

121. (New) The composition of Claim 108, wherein the compound is of the formula:

$$F_3C$$
 CF_3

(New) A method for inhibiting Fc receptor binding of immunoglobulin in a patient comprising administering to such patient a pharmaceutically effective amount of a compound of the formula:



or salts thereof,

wherein

each of W1 and W2 is independently CO2R3, C(=NH)NH(OH), PO(OR3)2 or

 $C(=O)CF_3;$

each of R¹ and R² is a bond, CH₂ or C₁-C₆ alkylene;

each of Ar¹ and Ar² is independently C₅-C₂₀ aryl or C₁-C₂₀ heteroaryl;

L is a linker comprising from 1 to about 20 atoms; and,

R3 is hydrogen or C. C. alkyl.

123. (New) The method of Claim 122, wherein said Fc receptor is selected from the group consisting of FcaR, FceR / EcvR and mixtures thereof.

124. (New) The method of Claim 122, wherein said Fc receptor is selected from the group consisting of FcγRIIa, μυνΙΙΒ, FcγRIIc and mixtures thereof.

125. (New) The method of Claim 122, wherein said method reduces IgG-mediated tissue damage in said patient.

126. (New) The method of Claim 122, wherein said method reduces inflammation in said patient.

127. (New) The method of Claim 122, wherein said method is used to treat an autoimmune disease.


128. (New) The method of Claim 122, wherein said method is used to treat a disease where aggregates of antibodies are produced or where immune complexes are produced by contact of antibody with intrinsic or extrinsic antigen.

129. (New) The method of Claim 128, wherein said disease is selected from the group consisting of immune complex diseases, autoimmune diseases, infectious diseases and vasculitities.


- 130. (New) The method of Claim 129, wherein said autoimmune disease is selected from the group consisting of rheumatoid arthritis, systemic lupus erythematosus, immune thrombocytopenia, neutropenia, and hemolytic anaemias.
- 131. (New) The method of Claim 129, wherein said vasculitities is selected from the group consisting of polyarteritis nodosa, and systemic vasculitis.
- 132. (New) The method of Claim 122, wherein said method is used to treat xenograft rejection.
- 133. (New) The method of Claim 129, wherein said infectious disease is selected from the group consisting of Dengue virus-dengue hemorrhagic fever and measles virus infection.
- 134. (New) The method of Claim 122, wherein said method reduces IgE-mediated response in said patient.

75 13/p


- 135. (New) The method of Claim 122, wherein said compound is selected from the group consisting of folic acid, 4-methyl benzoic acid, 3-methyl benzoic acid and a nucleoside or analogs thereof.
- 136. (New) The method of Claim 122, wherein said compound is of the formula:



137. (New) The method of Claim 122, wherein said compound is of the formula:



138. (New) The method of Claim 122, wherein said compound is of the formula:



- 139. (New) The method of Claim 138, wherein W¹ and W² are CO₂H.
- 140. (New) The method of Claim 138, wherein R¹ and R² are a bond.
- 141. (New) The method of Claim 140, wherein L^1 is L is selected from the group consisting of C_1 - C_{20} alkoxy, C_6 - C_{20} aryl and C_1 - C_6 heteroaryl.
- 142. (New) The method of Claim 140, wherein L is -CH₂O-.

MC17.

143. (New) The method of Claim 140, wherein L is a moiety of the formula:

Z/W

144. (New) The method of Claim 40, wherein L is a moiety of the formula:

wherein each of R⁴ and R⁵ is independently H, C₁-C₆ alkyl, C₈-C₁₀ aralkyl or a protecting group.

145. (New) The method of Claim 140, wherein the compound is of the formula:

146. (New) The method of Claim 140, wherein the compound is of the formula:

Q/w

148. (New) The method of Claim 140, wherein the compound is of the formula:

needszy. Tieot

149. (New) The method of Claim 140, wherein the compound is of the formula:

150. (New) The method of Claim 140, wherein the compound is of the formula: